Have questions about the economic measures put in place to support businesses affected by the coronavirus (COVID-19)? Visit the Québec.ca website.
La page est en cours de chargement...
Québec is fertile ground for collaborative health research. It has:
Six research focus areas
Website: University of Montreal Hospital Center - Research center
Eleven research focus areas
Website: Research Institute of the McGill University Health Centre
Five child-oriented research themes
Website: Sainte-Justine University Hospital - Research center
Six research themes
Website: Centre de recherche clinique of the Centre hospitalier universitaire de Sherbrooke
Seven research themes
Website: Centre hospitalier universitaire de Québec - Research center
Created in 2015, C3I accelerates patient access to innovative cancer immunotherapies, providing an integrated structure for their development, application and commercialization.
It provides cutting-edge biomarker and diagnostic tests, best practice standards in manufacturing, early access to clinical trials and regulatory support to bring quick, effective and affordable care to Canadians and people around the world.
C3I solidifies Québec’s position as a leader in cancer immunotherapy.
It helps health professionals and patients get early access to promising therapies at the developmental stage.
Key partnerships between C3I and pharmaceutical companies have paved the way for the first clinical trials in Québec using cutting-edge technology based on cellular therapy.
Centre d’excellence en thérapie cellulaire* (CETC) is one of the units C3I represents. CETC is a fully operational state-of-the-art laboratory that specializes in developing cellular therapy in accordance with current best manufacturing practices (BMP), in particular cancer immunotherapy treatments. Located at Hôpital Maisonneuve-Rosemont, CETC facilities are validated and meet the requirements of Canadian regulators, the EMA and the FDA.
*In French only.
Established in 2008, IRICoR is an integrated not-for-profit drug discovery and commercialization centre affiliated with the IRIC. Its mission is ensure the development of the most promising projects of the IRIC, other Université de Montréal units and various organizations in order to promote financial and strategic partnerships to accelerate the commercialization of new therapies in cancer, immunology and related fields.
So far, IRICoR has:
The institute has generated $6 in profits for each dollar in initial funding.
MHICC, a division of the MHI
, is a university clinical research organization. It provides a full range of services and serves the university community, pharmaceutical and biotechnological industries and medical devices sector in the following areas:
Affiliated with Université de Montréal, the MHI is highly specialized in cardiology. Averaging $705,500 in investment per researcher, the hospital leads Canada in terms of research intensity.
Q-CROC is a provincial clinical cancer research interface that serves as a bridge between:
The Consortium leverages its knowledge to make clinical research in Québec more competitive and attract more studies to the province.
It also contributes to the growth of a research niche aimed at discovering and validating biomarkers that will allow us to predict responses and resistance to treatments.
CQDM is a pre-competitive drug discovery research consortium set up to fund the development of breakthrough tools and technologies enhancing the productivity of biopharmaceutical R&D. CQDM is jointly funded by the Government of Québec and nine major pharmaceutical companies:
The TransMedTech Institute works to develop medical diagnosis and treatment technologies, especially in the fields of orthopedics, cardiovascular disease and oncology. It comprises Polytechnique Montréal and a number of other university hospital research centres.
The institute features an open innovation ecosystem driven by engineers, biomedical scientists, clinicians, patients, students, healthcare workers and policy-makers.
The TransMedTech Institute’s R&D activities are directly focused on the needs of patients, healthcare professionals and the healthcare system.
Led by Campus Montréal, a joint initiative by Université de Montréal, HEC Montréal and Polytechnique Montréal, IVADO’s goal is to create synergy between its three fields of expertise:
With over 900 affiliated scientists, IVADO provides a link between academic expertise and the needs of businesses, from startups to multinationals.
IRIC, Université de Montréal’s cancer research centre, has adopted a model that’s unique in Canada. Its mission is to study cancer mechanisms and to accelerate the discovery of more effective cancer therapies.
IRIC boasts a team of 500 and the most impressive biomedical research technology park in Canada, which is also used by other research centres.
The McGill University and Génome Québec Innovation Centre has over 80 employees. It’s the main genomics platform in Canada.
By supporting more than 80 projects and 900 researchers and managing the Innovation Centre’s activities, Génome Québec is accelerating the arrival of new applications in strategic sectors such as:
Over the years, the Innovation Centre has built extensive expertise in the area of complex genetic disorders. A third of its activities are currently aimed at clients outside Québec.
In November 2012, the Government of Québec teamed up with private partners AstraZeneca and Pfizer to launch NEOMED and the NEOMED Institute.
Since 2016, Janssen and Purdue Pharma have also joined the initiative. Furthermore, GSK will be investing $47 million in the Biologics and Vaccine Centre of Excellence. Created in 2015, this centre is unique in Canada.
NEOMED is a not-for-profit research consortium that operates as a conventional biotech company. NEOMED oversees its own drug development projects.
The NEOMED Institute has operated out of AstraZeneca’s former facilities in Technoparc Montreal since 2012, and also out of the former GSK Vaccines research centre in Laval—where the Biologics and Vaccine Centre of Excellence was established—since February 2015.
These two state-of-the-art R&D facilities serve as open-access hubs bringing together various companies and independent organizations with a view to fostering collaboration, innovation and creativity.
In less than five years, 29 companies and organizations have set up shop at the two facilities, which now have 340 employees.
Launched in February 2017, Oncopole is a research, development and investment hub aimed at accelerating the fight against cancer.
It gathers various partners around a capacity-building project. Oncopole is a one-of-a-kind co-creative partnership with an inclusive ideation and implementation process connected to the scientific community.
Fonds de recherche du Québec-Santé (FRQS) and Merck jointly announced this initiative, and the latter will be investing $15 million in it by 2020.
FRQS and Merck hope this initial funding will encourage other partners to join Oncopole and transform this project into a major oncology innovation hub.